Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Global Pharmaceuticals Business (Biopharma) Earnings

Global Pharmaceuticals Business (Biopharma) Earnings % Chg.

Global Pharmaceuticals Business (Biopharma) Earnings Common Size

Other Business Activities Earnings

Other Business Activities Earnings % Chg.

Other Business Activities Earnings Common Size

Other EBT

Other EBT % Chg.

Other EBT Common Size

Total EBT

Total EBT Common Size

Total EBT % Chg.

Comirnaty Direct Sales and Alliance Revenue

Comirnaty Direct Sales and Alliance Revenue % Chg.

Eliquis Alliance Revenue and Direct Sales

Eliquis Alliance Revenue and Direct Sales % Chg.

Prevnar Revenue

Prevnar Revenue % Chg.

Paxlovid Revenue

Paxlovid Revenue % Chg.

Prevnar Family Revenue

Prevnar Family Revenue % Chg.

Nurtec ODT/Vydura Revenue

Nurtec ODT/Vydura Revenue % Chg.

Abrysvo Revenue

Abrysvo Revenue % Chg.

Vyndaqel Family Revenue

Vyndaqel Family Revenue % Chg.

Xeljanz Revenue

Xeljanz Revenue % Chg.

Ibrance Revenue

Ibrance Revenue % Chg.

Consumer Healthcare Revenue

Consumer Healthcare Revenue % Chg.

Vaccines Revenue

Vaccines Revenue % Chg.

Internal Medicine Revenue

Internal Medicine Revenue % Chg.

Hospital Revenue

Hospital Revenue % Chg.

Inflammation & Immunology Revenue

Inflammation & Immunology Revenue % Chg.

Rare Disease Revenue

Rare Disease Revenue % Chg.

Key Performance Indicators

Revenue by Geography

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

Developed Markets Revenue

Developed Markets Revenue % Chg.

Developed Markets Revenue Common Size

Emerging Markets Revenue (Post-FY2023 Reporting)

Emerging Markets Revenue (Post-FY2023 Reporting) % Chg.

Emerging Markets Revenue (Post-FY2023 Reporting) Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Developed Europe Revenue

Developed Europe Revenue % Chg.

Developed Europe Revenue Common Size

Developed Rest of World Revenue

Developed Rest of World Revenue % Chg.

Developed Rest of World Revenue Common Size

Emerging Markets Revenue

Emerging Markets Revenue % Chg.

Emerging Markets Revenue Common Size

International Revenue

International Revenue % Chg.

International Revenue Common Size

Primary Care Revenue

Primary Care Revenue % Chg.

Primary Care Revenue Common Size

Specialty Care Revenue

Specialty Care Revenue % Chg.

Specialty Care Revenue Common Size

Oncology Revenue

Oncology Revenue % Chg.

Oncology Revenue Common Size

Global Pharmaceuticals Business (Biopharma) Revenue

Global Pharmaceuticals Business (Biopharma) Revenue % Chg.

Global Pharmaceuticals Business (Biopharma) Revenue Common Size

Business Innovation (Pfizer CentreOne) Revenue

Business Innovation (Pfizer CentreOne) Revenue % Chg.

Business Innovation (Pfizer CentreOne) Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
Primary Care Revenue	7,646	5,540
Specialty Care Revenue	4,411	4,378
Oncology Revenue	4,253	4,387
Global Pharmaceuticals Business (Biopharma) Revenue	16,310	14,305
Business Innovation (Pfizer CentreOne) Revenue	344	328
Other Revenue	—	20
Total Revenue	16,654	14,653

Revenue by Geography	Sep '25	Jun '25
United States Revenue	10,691	8,894
Developed Markets Revenue	3,696	3,393
Emerging Markets Revenue (Post-FY2023 Reporting)	2,267	2,366
Other Revenue by Geography	—	—
Total Revenue by Geography	16,654	14,653

Revenue by Geography	Sep '25	Jun '25
United States Revenue	10,691	8,894
Developed Europe Revenue	—	—
Developed Rest of World Revenue	—	—
Emerging Markets Revenue	—	—
International Revenue	5,963	5,759
Other Revenue by Geography	—	—
Total Revenue by Geography	16,654	14,653

EBT	Sep '25	Jun '25
Global Pharmaceuticals Business (Biopharma) Earnings	8,469	6,929
Other Business Activities Earnings	-3,084	-1,799
Other EBT	-2,051	-2,086
Total EBT	3,334	3,044

Key Performance Indicators	Sep '25	Jun '25
Comirnaty Direct Sales and Alliance Revenue	1,151	381
Eliquis Alliance Revenue and Direct Sales	2,015	2,003
Prevnar Revenue	—	—
Paxlovid Revenue	1,225	427
Prevnar Family Revenue	1,742	1,383
Nurtec ODT/Vydura Revenue	412	359
Abrysvo Revenue	279	143
Vyndaqel Family Revenue	1,591	1,615
Xeljanz Revenue	313	322
Ibrance Revenue	1,057	1,049
Vaccines Revenue	—	—
Internal Medicine Revenue	—	—
Hospital Revenue	—	—
Inflammation & Immunology Revenue	—	—
Rare Disease Revenue	—	—